Bayesian analysis using a virus dynamics model is demonstrated to facilitate hypothesis testing of patterns in clinical time-series. Our Markov chain Monte Carlo implementation demonstrates that the viraemia time-series observed in two sets of hepatitis B patients on antiviral (lamivudine) therapy, chronic carriers and liver transplant patients, are signi¢cantly di¡erent, overcoming clinical trial design di¡erences that question the validity of non-parametric tests. We show that lamivudine-resistant mutants grow faster in transplant patients than in chronic carriers, which probably explains the di¡erences in emergence times and failure rates between these two sets of patients. Incorporation of dynamic models into Bayesian parameter analysis is of general applicability in medical statistics.
INTRODUCTION
Therapy development for fatal diseases presents major challenges for medical statistics. Reliable signi¢cance tests based on minimal clinical data are required to make informed decisions about ongoing treatments and clinical trials. Such data sets may be unique and irreproducible because therapies can turn out to be unjusti¢able over the course of a clinical trial; however, such trials may be highly informative, especially as they represent direct consequences of risk factors. For instance, some of the participants in a clinical trial of high viraemia patients for the treatment of end-stage hepatitis B virus (HBV)-associated liver disease using the anti-viral drug lamivudine and liver transplantation had HBV reemerge. Because reinfection following liver transplantation has potentially fatal consequences this treatment has since been modi¢ed; the original patient cohort thus provides a unique set of data which may never be duplicated. Analysis of clinical data sets normally use nonparametric statistics such as the Mann^Whitney rank test. However, the small size of the data sets may mean that such tests have insu¤cient power. More powerful tests can be constructed using virus dynamic models that can be tailored individually to the trial. With the development of Markov chain Monte Carlo (MCMC) methods (Gilks et al. 1996) these tests are realistic and feasible. MCMC is an ideal method for such analyses because of its immense £exibility, and has already been used in a variety of instances in medicine (Gilks et al. 1993; Spiegelhalter et al. 1996) .
In this paper we compare antiviral treatment of HBV between liver transplant and non-transplant patients, examining the hypothesis that the rate of mutant growth is di¡erent in the two groups, and propose that this disparity is responsible for the di¡erences in the observed emergence times. Traditional non-parametric analysis is of questionable validity because of di¡erences in experimental design between the two data sets that may lead to a high type I error in these tests. Our analysis using a novel MCMC method demonstrates that HBV lamivudineresistant mutants have a signi¢cantly faster replication cycle in transplant patients, and is a contributing factor in the di¡erences between transplant and non-transplant patient prophylaxis failure. Such an analysis is vital for the informed use of immunosuppressive drugs in patients with HBV, the adaptation of therapies between these patient groups, and the development of new drug targets through a greater understanding of the virus life cycle and viral ecology.
CLINICAL DATA
Liver transplantation o¡ers the only treatment option for patients with end-stage HBV-associated liver disease. However, this was once restricted to low viraemia patients because those with high virus titres (greater than 10 6 copies ml
71
) have a poor prognosis resulting from a high probability of HBV recurrence. Re-emergence under immune suppression (required for transplant) causes severe hepatitis (Davies et al. 1991) . The high e¤ciency of the antiviral drug lamivudine in reducing virus levels in non-transplant patients suggested that treatment of high viraemia patients may be possible. However, in a cohort of nine patients treated with lamivudine, three developed lamivudine-resistant mutants (¢gure 1 and table 1) as veri¢ed by sequencing (Cane et al. 1999) . Such a study raises a number of questions (Burroughs et al. 1998; Mutimer et al. 1999) , in particular why re-emergence appears to be more frequent in transplant patients than non-transplant patients (307 and 147 failure over one year of treatment, respectively; Lai et al. 1998) .
To examine the problem, this data set (together with data pertaining to a transplant patient from another study) was compared with data from a set of six chronic HBV carriers who had developed lamivudine-resistant mutants was compared with data from a set of six chronic HBV carriers who developed lamivudine-resistant mutants while on lamivudine monotherapy (¢gure 2). Five of these patients had previously received combination therapy (interferon-a + lamivudine) for a short time (less than 140 days); however, the time interval between these treatments is believed to be su¤cient not to cause any signi¢cant change in the HBV-infected hepatocyte population. Emerging populations are all veri¢ed to be lamivudine-resistant mutants by sequencing and are either dominated by a single mutant strain, or are an apparently stable mixture. Data from these patients are summarized in table 2. We use the pre¢xes NTX and TX to distinguish chronic and transplant patients, respectively.
Comparison of these two data sets indicates that the mutant emerges (relative to start of therapy) signi¢cantly earlier in transplant patients (average 374 days, s.d. 44 days, three patients) relative to non-transplant patients (average 570 days, s.d. 150 days, six patients), ( p 0:056 rank test). This earlier emergence has also been observed in lamivudine therapy of transplant patients where therapy starts a signi¢cant period after transplant (Perrillo et al. 1999) . The simplest explanation of this e¡ect is a faster growth rate of mutants in transplant patients as suggested by a linear regression analysis on the data sets (table 2) ( p < 0:005 Mann^Whitney). However, such an analysis is of questionable validity, because the time resolution of the non-transplant data is insu¤cient to guarantee that the emergence of the mutant has, in fact, been captured. A typical time-series consists of a viraemia plateau corresponding to the wildtype virus under lamivudine before emergence, a higher plateau corresponding to the lamivudine-resistant mutant steady state after emergence, and an intermediate value at a single time-point (¢gures 2 and 3). In ¢ve of the chronic patients (patients 1^5, ¢gure 2) there are insu¤-cient time-points to perform a linear regression because there is no guarantee that the mutant dominated at the lowest time-point, i.e. was just about to emerge, or had just ¢nished exponential growth at the top point. Sequencing at these data points was not able to provide any further information, and invariably suggested that the mutant was a minority species at a relative frequency of less than 57 (detection limit) at the time-point at the base of the supposed emergent growth phase. This contrasts with the transplant data in which growth has been captured principally because of the higher time The lines shown are the best ¢t for the growth and decay phases. Transplantation occurred at day 0, and lamivudine was administered before transplantation as indicated by the arrow. Bars are 957 con¢dence intervals; half-bars indicate readings above or below the detection limit. Under immune suppression, ¢nal viraemia (for those patients that acquired resistant mutants) was higher than the initial chronic state because nearly all hepatocytes were infected (Davies et al. 1991) , and thus all patients had a ¢nal viraemia above 10 7 copies ml 71 . HBV DNA was measured by ligand hybridization (Abbott, Abbott Diagnostics Division, Maidenhead, Berkshire, UK) and quantitative PCR (Roche Amplicor, Roche Diagnostics Ltd, Lewes, East Sussex, UK). Abbott was used to extrapolate readings above 4Â10 7 copies ml À1 , the limit of the Roche assay.
resolution and greater di¡erence in initial and ¢nal viraemia (¢gure 1). An improvement on a linear regression analysis is based on the maximum observed growth between any two data points for which emergence is evident (i.e. viraemia remains higher than that at the earlier timepoint). This does not assume that there are three data points on the emerging mutant growth phase. Such an analysis indicates that there are signi¢cant di¡erences between the data sets ( p50:005 Mann^Whitney rank test), using the values given in tables 1 and 2. However, this test is also questionable because the signi¢cance of this result may be due to the di¡erent time intervals between observations or the viraemia range di¡erences of the two data sets. Both of these e¡ects bias towards rejecting the null hypothesis when it is true, i.e. high type I error, because the estimated growth rate between two points may be less than the actual mutant growth rate (those two points are not necessarily on the growth phase).
ANALYSING THE GROWTH RATE
The high correlation coe¤cients observed in the linear regression analysis of the growth phase in the nontransplant patients suggests that the time-series is, in fact, representative of the growth of the mutant (table 3) . To con¢rm that this is the case, and that the growth rate is not as high as that observed in the transplant patients, we constructed a hypothesis test for observing time-series patterns. The basic idea of the test is that if the emerging strain has a high growth rate it is very unlikely that a time-point in the exponential growth phase of the mutant would actually be observed. For instance, if it takes ten days to increase the viraemia from the lower to a higher plateau, a time resolution of 60 days only has a one in six chance of an observation lying on the growth phase. Therefore the probability of observing a signi¢cant point on the growth phase is less than one in six in this example.
The viraemia time-series can be described to a good approximation by a piecewise linear growth model (¢gure 3) ( y log e v the natural logarithm of the viraemia),
with the mutant numerically dominating from time t * , and r is the mutant growth rate. Here L and H are the (natural logarithms of the) lower and higher steady states. The variable y is the expectation of the log Testing of clinical data using virus dynamics models N. J. Burroughs and others 2361
Proc. R. Soc. Lond. B (1999) The ¢nal patient is from a di¡erent study who had a pre-treatment viraemia below 400 copies ml 71 , and lamivudine therapy started a week after transplant. Therefore this patient is not included in the emergence time analysis, but only used for growth rate comparison. viraemia. Although a logistic growth model would be more natural, this approximation is easier to implement in the MCMC algorithm (see Appendix A), and both capture the exponential growth phase that dominates the dynamics (¢gure 1). Under growth model (1) the predicted viraemia of a time-point intermediate between two measurements that encircle the growth phase can be computed. This is a Bayesian calculation of the observed viraemia at a time-point t P t L , t H , conditional on the fact that the mutant was a minority population at time t L , numerically dominated at time t H and the mutant grew with rate r. This is a suitable model for the emergence of a mutant, because the time interval t L , t H is short compared with the time since the start of therapy; therefore a uniform distribution is appropriate. In practice, the actual interval t L , t H is not important because the data determine the time-frame of the plateaus and emergence is trapped between observations at these two levels. Thus, in ¢ve patients we take t L within 200 days of the start of treatment because the pre-resistance plateau is established by that time. In patient NTX3 the viraemia continued to decay after an initial rapid exponential decline (¢gure 2) presumably caused by the clearance of infected hepatocytes (Nowak et al. 1996; Burroughs et al. 1998) , and thus the viraemia failed to settle to a steady state. This means that only a small number of time-points near the end of this decay phase can be used in the analysis (those which conform approximately to the model of ¢gure 3), or the model should be adapted to include such a decay phase. We adopt the former method for simplicity, and this reduces the power of our test on this patient. The likelihood of observing an intermediate viraemia value is best illustrated by the probability density function (PDF) of a single measurement at time t,
where y(t) is given by equation (1). Imposing the prior t * P t L , t H , the variable t * can be integrated out to give Only patients 1 (a), 3 (b) and 6 (c) are shown (one other patient had a similar viraemia pro¢le to patient 1, and two others to patient 3, although only patient 3 displayed a continued decline; the others plateaued soon after the start of therapy Here we have de¢ned w (H À L)=r, and our expression assumes t P (t L w, t H ). In the limit 3 0 this expression reduces to the expected time-partition result:
, and uniform in L,H with probability w/(t H À t L ). For non-zero , the PDF is a convolution of this distribution with the Gaussian distribution. Thus for high growth rates r, the distribution for is peaked at L and H, while for low r the distribution is broad with Gaussian decay above H and below L. Such a probability density allows assessment of the probability of observing a viraemia lying in the central uniform valley. Incorporation of additional observations e¡ectively limits the likely values of t * , i.e. an observation H close to L at t 1 gives a weighting exp (À ( 1 À L) 2 / 2 2 ): exp (À ( 1 À H) 2 /2 2 ) in favour of t * 4t 1 . In order to compute the probability distribution for the viraemia at time t k , we use the following likelihood:
where the observed viraemia at t i is i , y(t) is de¢ned in equation (1), and the measurement at time t k is omitted. A Markov chain for the variables t * , L and H computes the Bayesian probability P(t * , L, H, y(t k )jr, f i g iT k ) for an assumed growth rate r; see Appendix A. The PDF of the predicted observation at time t k , P( k jr,f i g iT k ), now follows. This can be performed either for a ¢xed r, or using a given PDF for r, e.g. estimated from the transplantation data.
The priors used for L and H are N(10, 10) and N(20, 3). The former is very weak because the data strongly determine L. However, the higher plateau H is determined only by 1^3 data points depending on the patient; thus we use a stronger prior that re£ects the fact that all patients have an initial steady-state viraemia in the range 10 7^1 0 9 copies ml À1 and the ¢nal viraemia is expected to be of this order.
We assume measurement errors are normally distributed: calculating the standard deviation from the fact that half a log 10 di¡erence between two independent measurements is normally considered signi¢cant for the polymerase chain reaction (PCR). We interpret this as a 907 signi¢cance level, giving a standard deviation for
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(a) Results
The posterior distribution for viraemia of patient NTX3 748 days after the start of lamivudine therapy is shown in ¢gure 4, assuming that the growth rate for the mutant is 0.12 day
À1
, the slowest growth rate observed in the transplant patients (table 1). The observed viraemia is within the central (uniform) valley of the distribution, within the central 0.67 of the distribution (table 3) . This clearly demonstrates that the time-series observed for this patient is signi¢cantly di¡erent from that of a mutant that grows at 0.12 day
. The observed time-series becomes more probable as the assumed growth rate is reduced. Choosing appropriate time-points for the other nontransplant patients we ¢nd that all six patients have timeseries that are signi¢cantly di¡erent ( p50:05) from those expected if the mutants grow at a rate as high as 0.12 day À1 (table 3) . This result has only a weak dependence on the priors. The regression coe¤cient PDF is also calculated for the predicted point and the two surrounding observations. This PDF con¢rms the conclusions in most of the patients (table 3) , and supports the earlier comment that these regression coe¤cients are high.
(b) Estimating the growth rate
The previous test has demonstrated that the data strongly support the hypothesis that the growth rate of lamivudine-resistant mutants is higher in transplant patients compared with chronic carriers (no signi¢cant liver disease). In this section we consider direct estimation of resistant mutant growth rates in the chronic carriers. The earlier Markov chain can be modi¢ed to incorporate the growth rate r and therefore calculate the probability distribution P(r, t * , L, Hjf i g i ), and thus the desired distribution P(rjf i g i ). The low resolution of the data in the growth phase means that these distributions are only de¢ned within the context of priors on r which limit high growth rates. The distribution P(rjf i g i ) is predicted to have a behaviour a b/r for large r; the 1/r decay occurs when there is a single datum point on the growth phase which restricts the location of the growth phase but not the growth rate, which can be arbitrarily large, while the constant asymptotic value as r tends to in¢nity derives from gaps in the time-series which separate observations that are basically L from those that are basically H. In such a region, the growth rate can be arbitrarily large and growth initiated (t * ) anywhere in that interval. If an intermediate viraemia is observed, this asymptotic value is very low because the intermediate value contributes the smaller of exp (À ( À L) 2 /2 2 ) or exp (À ( À H) 2 /2 2 ). For low r, the distribution declines rapidly below the mode as in normal regression analysis, because the data strongly restrict low growth rates (¢gure 5).
Because the distributions P(rjf i g i ) are normalized through a prior, it is important that the prior is su¤-ciently weak. We choose a uniform prior r P 0, 0:35, the upper limit being larger than any of the growth rates observed in the transplant patients. A uniform distribution is preferable (compared to a normal prior) because it does not distort the probability distribution and allows the tails to be compared with the predicted form. These distributions are shown in ¢gure 5 and have asymptotic tails a b/r as required when r tends to in¢nity. The mode is prior independent and agrees with the linear regression gradient estimate (table 3) . Distribution moments depend strongly on the prior for r since the asymptotic tail is not normalizable, and thus the estimated growth rates must be viewed within the context of this prior.
The PDF values for r can be used to compute an estimate of the population mean by averaging, r pop est (1/n) P r i . Strictly, this distribution should be computed within MCMC using a Markov chain incorporating the six nontransplant data sets (Gilks et al. 1996) . We obtain a population growth rate of 0.105 (s.d. 0.035) day
À1
, with a PDF that is approximately normal (¢gure 5). This population growth rate is signi¢cantly di¡erent from the transplant estimate at 907 signi¢cance, p50:10 by a direct comparison of the PDF of r pop est and the transplant estimate N(0.179, 0.045). There are a number of factors that can a¡ect the signi¢cance of this result, principally the measurement error standard deviation (increasing this by 157 takes p $ 0:25) and the prior r, because the underlying conditional is not normalizable. However, our estimate of the measurement error supports the traditional error estimates to within 2.5%, and r P 0, 0:35 is very reasonable because growth rates higher than 0:35 day À1 are unrealistic and have not been observed.
CONCLUSIONS
Our primary aim in this analysis was the general demonstration that MCMC can be used to construct tests on di¤cult clinical data where non-parametric methods may be of questionable validity. This was illustrated through the speci¢c construction of a test to compare the growth rates of lamivudine-resistant mutants in transplant and non-transplant HBV patients, regression analysis and non-parametric tests in this case possibly being prone to large type I errors originating from di¡er-ences between the data sets in the time-periods between observations and viraemia ranges. MCMC methodology allowed model-speci¢c hypotheses to be constructed which incorporated virus growth dynamics and overcame these clinical design di¡erences. This method is of general applicability to time-series analysis and/or comparisons where the underlying dynamics are understood. Incorrect dynamic model hypotheses would invalidate the conclusions; however, the method can be extended to also compare possible models (Gelman & Meng 1996) .
Our analysis was conclusive in determining that the viraemia time-series of each chronic patient was not consistent with a mutant growth rate as high as that observed in transplant patients (0:12 day À1 ), p < 0:05. This was extended to a population comparison by controlling large growth rates with suitable priors, giving similar but less signi¢cant results, p50:10. We conclude that lamivudine-resistant mutants have signi¢cantly higher growth rates in transplant patients compared with non-transplant patients, resulting either from an increase in infection pressure caused by immunotherapy as observed in vitro (increased virion productivity; McMillan et al. 1995) , the reduction in clearance of infected cells because of immunotherapy, or an increase in the number of susceptible cells at transplant. The di¡erence in growth rates is probably signi¢cant in explaining the di¡erence in emergence times (tables 1 and 2) and the higher failure rate (307) in transplant patients over the ¢rst year compared with non-transplant patients (147; Lai et al. 1998) . This is because the virus growth cycle is faster in transplant patients and therefore failure occurs on a faster time-scale. In con¢rmation, over a two year time-frame non-transplant patients also have a failure rate of 203 07 (Leung et al. 1999) .
Our Bayesian analysis could be improved through incorporation of the sequence data. Sequencing indicates that at the time-points at the base of the emergent phase the mutant had a relative frequency of less than 57. Such information could easily be incorporated into the Markov chain. Improvements in the resolution of the data, and especially of the emerging phase, would be very valuable. However, given the probability of emergence (307 over two years) and distribution of emergence times (mean 570 days, s.d. 150 days), obtaining three data points on the growth phase will be expensive, di¤cult and will take two to three years. This justi¢es the use of powerful statistical parametric tests to maximize the use of existing clinical trials. Use of PCR techniques to detect YMDD mutants at low concentrations (Chayama et al. 1998 ) may allow resolution to be appropriately adjusted in future trials.
APPENDIX A
In this appendix we outline the construction of the Markov chain and its update algorithm. The Markov chain consists of the two steady-state (log e ) viraemias L and H, the time after which the mutant numerically dominates t * , and the growth rate of the mutant r. The observed viraemia (natural logarithm) i at time t i has mean y(t i ), (1) and standard deviation (measurement error) , i.e. i $ N( y(t i ), ). The likelihood is given by
Gibbs algorithms for updating the variables can be expressed in terms of cut and pastes of normal and uniform distributions, i.e. a continuous distribution that has sections that are normal or uniform. Drawing from such distributions requires the probability of being in each section, and then drawing from the appropriate truncated distribution.
To update H, de¢ne the boundaries h i L r(t i À t * ), then
where products over i are restricted to those satisfying t i 4t * . A weak prior N(H 0 , H ) is used, and we further restrict H4L. Similarly, to update L, de¢ne the boundary l i H À r(t i À t * ) when t i 4t * , then
A weak prior N(L 0 , L ) is used, and we further restrict L5H. Because L and H are logarithms there are no positivity restrictions. The distributions (Lj Á ), (Hj Á )
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where we restrict t * P t L , t H by a uniform prior, where t H and t L are suitably chosen to safely encircle the mutant exponential growth phase. Here we have used the notation t * 5 i to mean t * 5t Vt P i . The distribution (t * j Á ) therefore consists of sections of uniform and normal distributions with boundaries at end-points of i , and at t L , t H , and is continuous as demonstrated by examination of equation (A4).
These three distributions are su¤cient to calculate the distribution of any observation at a given time, for speci¢ed growth rate r. Thus the probability of observing an intermediate viraemia on the growth phase can be computed, testing whether the observed value is likely directly from the con¢dence interval of the PDF.
To calculate the PDF of the growth rate r, an update for r must be determined. Consider the set of observations i with t i > t * , and de¢ne i (H À L)/(t i À t * ). Then the conditional probability is a cut^paste distribution with boundaries at i given by 
We restrict r P 0,r 0 through a uniform prior. Two properties of the PDF for r can be deduced from the likelihood (A1) for the case of two observations that generalize to the general case (¢xed L, H). First, for large r the asymptotic form P(rjf i g) $ a b r , A6
follows by integration over t * . Second, if the points lie on the growth phase P(r, t * jf i g) $ 1 r exp À 1 2
where Á i i À " , " being the mean of the observed values, and similarly for Át i . Thus the mode for two observations is approximately ( 2 À 1 )/(t 2 À t 1 ) as expected, with an approximately Gaussian distribution. The pre-factor of 1/r arises because of the parametrization of the regression line as y r(t À t * ) instead of the more common y rt a. The latter is unsuitable because the time-region includes the emergence event, and is therefore conditional on growth occurring from L to H in the interval t L , t H .
